Submitted:
25 April 2026
Posted:
28 April 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Molecular-Level Investigation of Non-Alcoholic Fatty Liver Disease
3. Origin and Biological Characteristics of the Wnt Pathway
4. The Role of the Wnt/β-Catenin Pathway in the Liver
4.1. Liver Sinusoidal Cells
4.2. Hepatic Stellate Cells
4.3. Bile Duct Cells
4.4. Immune Cells in the Liver
5. Mechanism Study of UCMSC in Improving NAFLD
5.1. Umbilical Cord Blood/UC Blood Mesenchymal Stem Cells
5.2. MSC and Related EVs
5.3. UCMSC Inhibition of Inflammation and Fibrosis NF-KB Treatment of NAFLD
5.5. UCMSC Improve FFAs Treatment for NAFLD
6. UCMSC-Mediated Multidimensional Culture Improves NAFLD
7. Summary
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- ALAMI, F.; ALIZADEH, M.; SHATERI, K. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial[J]. Scand. J. Gastroenterol. 2022, 57(10), 1238–1249. [Google Scholar] [CrossRef]
- ZHU Y.L., MENG L.L., MA J.H., et al. Loss of LBP triggers lipid metabolic disorder through H3K27 acetylation-mediated C/EBPβ-SCD activation in non-alcoholic fatty liver disease[J]. Zool Res, 2024, 45(1): 79-94. [CrossRef]
- TASLIM, N.A.; YUSUF, M.; AMBARI, A.M.; et al. Anti-Inflammatory, Antioxidant, Metabolic and Gut Microbiota Modulation Activities of Probiotic in Cardiac Remodeling Condition: Evidence from Systematic Study and Meta-Analysis of Randomized Controlled Trials[J]. Probiotics Antimicrob. Proteins 2023, 15(4), 1049–1061. [Google Scholar] [CrossRef]
- SMITH, G.I.; SHANKARAN, M.; YOSHINO, M.; et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J]. J. Clin. Invest 2020, 130(3), 1453–1460. [Google Scholar] [CrossRef]
- SCUTIERO, G.; IANNONE, P.; BERNARDI, G.; et al. Oxidative Stress and Endometriosis: A Systematic Review of the Literature[J]. Oxid. Med. Cell. Longev. 2017, 2017, 7265238. [Google Scholar] [CrossRef]
- DING, K.; ZHANG, Z.; HAN, Z.; et al. Liver ALKBH5 regulates glucose and lipid homeostasis independently through GCGR and mTORC1 signaling[J]. Science 2025, 387(6737), eadp4120. [Google Scholar] [CrossRef] [PubMed]
- NUCIFORO, S.; HEIM, M.H. Organoids to model liver disease[J]. JHEP Rep. Innov. Hepatol. 2020, 3(1), 100198. [Google Scholar] [CrossRef] [PubMed]
- YANG, F.; WU, Y.; CHEN, Y.; et al. Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis[J]. JHEP Rep. Innov. Hepatol. 2023, 5(7), 100746. [Google Scholar] [CrossRef]
- BARANOVA, A.; MALTSEVA, D.; TONEVITSKY, A. Adipose may actively delay progression of NAFLD by releasing tumor-suppressing, anti-fibrotic miR-122 into circulation[J]. Obesity reviews: an official journal of the International Association for the Study of Obesity 2019, 20(1), 108–118. [Google Scholar] [CrossRef] [PubMed]
- ZHANG, B.; ZHANG, B.; LAI, R.C.; et al. MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH[J]. Int. J. Mol. Sci. 2023, 24(9), 8092. [Google Scholar] [CrossRef]
- MOAYEDFARD, Z.; SANI, F.; ALIZADEH, A.; et al. The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles[J]. Stem Cell. Res. Ther. 2022, 13(1), 242. [Google Scholar] [CrossRef]
- KHOLODENKO, I.V.; YARYGIN, K.N. Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis[J]. Biomedicines 2023, 11(11), 3056. [Google Scholar] [CrossRef] [PubMed]
- DORAIRAJ, V.; SULAIMAN, S.A.; ABU, N.; et al. Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update[J]. Biomolecules 2020, 10(11), 1494. [Google Scholar] [CrossRef] [PubMed]
- YAN, F.J.; DING, H.; ZHANG, N.; et al. The E3 ligase tripartite motif 7 drives the progression of non-alcoholic fatty liver disease by targeting DUSP10 degradation in male mice[J]. Nat. Commun. 2025, 16(1), 10437. [Google Scholar] [CrossRef]
- ZHOU, Y.; WANG, G.; LIU, L.; et al. Cellular crosstalk mediated by Meteorin-like regulating hepatic stellate cell activation during hepatic fibrosis[J]. Cell. Death Dis. 2025, 16(1), 405. [Google Scholar] [CrossRef]
- YAN, F.J.; ZHANG, X.J.; WANG, W.X.; et al. The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis[J]. Hepatology 2017, 65(5), 1492–1511. [Google Scholar] [CrossRef]
- CHENG, X.; MA, X.; ZHU, Q.; et al. Pacer Is a Mediator of mTORC1 and GSK3-TIP60 Signaling in Regulation of Autophagosome Maturation and Lipid Metabolism[J]. Mol. Cell. 2019, 73(4), 788–802.e7. [Google Scholar] [CrossRef]
- DING, X.; JIANG, X.; TIAN, R.; et al. RAB2 regulates the formation of autophagosome and autolysosome in mammalian cells[J]. Autophagy 2019, 15(10), 1774–1786. [Google Scholar] [CrossRef] [PubMed]
- HUANG, Y.; YU, F.; DING, Y.; et al. Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver[J]. Hepatology 2025, 81(5), 1564–1582. [Google Scholar] [CrossRef]
- PETKEVICIUS, K.; PALMGREN, H.; GLOVER, M.S.; et al. TLCD1 and TLCD2 regulate cellular phosphatidylethanolamine composition and promote the progression of non-alcoholic steatohepatitis[J]. Nat. Commun. 2022, 13(1), 6020. [Google Scholar] [CrossRef]
- LI, B.; CHENG, Y.; YU, S.; et al. Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice[J]. Stem Cells Int. 2019, 2019, 8628027. [Google Scholar] [CrossRef]
- ALISON, M.R. Cholangiocytes: No Longer Cinderellas to the Hepatic Regenerative Response[J]. Cell. Stem Cell. 2017, 21(2), 159–160. [Google Scholar] [CrossRef] [PubMed]
- HOU, J.; ZHANG, J.; CUI, P.; et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis[J]. J. Clin. Invest 2021, 131(4), e135197. [Google Scholar] [CrossRef]
- HOU, X.; YIN, S.; REN, R.; et al. Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis[J]. Hepatology 2021, 74(1), 116–132. [Google Scholar] [CrossRef] [PubMed]
- SHEN, Y.; CHENG, L.; XU, M.; et al. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis[J]. Metabolism 2023, 146, 155657. [Google Scholar] [CrossRef] [PubMed]
- ZHOU, B.; LUO, Y.; BI, H.; et al. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11[J]. Cell. Metab. 2024, 36(10), 2228–2244.e7. [Google Scholar] [CrossRef] [PubMed]
- AHMED, H.; UMAR, M.I.; IMRAN, S.; et al. TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop[J]. Exp. Mol. Pathol. 2022, 124, 104733. [Google Scholar] [CrossRef]
- MARTINI, T.; NAEF, F.; TCHORZ, J.S. Spatiotemporal Metabolic Liver Zonation and Consequences on Pathophysiology[J]. Annu Rev. Pathol. 2023, 18, 439–466. [Google Scholar] [CrossRef]
- ZHOU, Y.; ZHAO, Y.; CARBONARO, M.; et al. Perturbed liver gene zonation in a mouse model of non-alcoholic steatohepatitis[J]. Metabolism 2024, 154, 155830. [Google Scholar] [CrossRef]
- LEE, D.S.; AN, T.H.; KIM, H.; et al. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice[J]. Diabetologia 2023, 66(5), 931–954. [Google Scholar] [CrossRef]
- KORIEM, K.M.M. Calculus bovis in hepatocellular carcinoma: Tumor molecular basis, Wnt/β-catenin pathway role, and protective mechanism[J]. World J. Gastroenterol. 2024, 30(35), 3959–3964. [Google Scholar] [CrossRef] [PubMed]
- NIAN, F.; CHEN, Y.; XIA, Q.; et al. Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance[J]. Int. Immunopharmacol. 2024, 142 Pt B, 113173. [Google Scholar] [CrossRef]
- SHREE HARINI, K.; EZHILARASAN, D. Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases[J]. Hepatobiliary Pancreat. Dis. Int. 2023, 22(4), 333–345. [Google Scholar] [CrossRef] [PubMed]
- OH, K.K.; GUPTA, H.; MIN, B.H.; et al. The identification of metabolites from gut microbiota in NAFLD via network pharmacology[J]. Sci. Rep. 2023, 13(1), 724. [Google Scholar] [CrossRef]
- ZHAO, H.; MING, T.; TANG, S.; et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol. Cancer 2022, 21(1), 144. [Google Scholar] [CrossRef]
- XU, X.; ZHANG, M.; XU, F.; et al. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities[J]. Mol. Cancer 2020, 19(1), 165. [Google Scholar] [CrossRef]
- STEINHART, Z.; ANGERS, S. Wnt signaling in development and tissue homeostasis[J]. Development 2018, 145(11), dev146589. [Google Scholar] [CrossRef]
- LI, C.; YANG, D.; WANG, X.; et al. ApoA5-CIDEC axis regulates hepatic lipid metabolism, inflammation, and fibrosis in MASLD[J]. J. Mol. Med. 2026, 104: 3. [Google Scholar] [CrossRef] [PubMed]
- HE, Q.; HE, W.; DONG, H.; et al. Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease[J]. Cell. Commun. Signal 2024, 22, 346. [Google Scholar] [CrossRef]
- LI, Z.W.; RUAN, B.; YANG, P.J.; et al. Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells[J]. Signal Transduct. Target Ther. 2023, 8(1), 344. [Google Scholar] [CrossRef]
- PABST, O.; HORNEF, M.W.; SCHAAP, F.G.; et al. Gut-liver axis: barriers and functional circuits[J]. Nat. Rev. Gastroenterol. Hepatol. 2023, 20(7), 447–461. [Google Scholar] [CrossRef]
- CASEY, L.M.; HUGHES, K.R.; SAUNDERS, M.N.; et al. Mechanistic contributions of Kupffer cells and liver sinusoidal endothelial cells in nanoparticle-induced antigen-specific immune tolerance[J]. Biomaterials 2022, 283, 121457. [Google Scholar] [CrossRef]
- DE HAAN, W.; DHEEDENE, W.; APELT, K.; et al. Endothelial Zeb2 preserves the hepatic angioarchitecture and protects against liver fibrosis[J]. Cardiovasc Res. 2022, 118(5), 1262–1275. [Google Scholar] [CrossRef]
- KAWASHITA, E.; OZAKI, T.; ISHIHARA, K.; et al. Endothelial group IVA phospholipase A(2) promotes hepatic fibrosis with sinusoidal capillarization in the early stage of non-alcoholic steatohepatitis in mice[J]. Life Sci. 2022, 294, 120355. [Google Scholar] [CrossRef]
- FURUTA, K.; TANG, X.; ISLAM, S.; et al. Endotheliopathy in the metabolic syndrome: mechanisms and clinical implications[J]. Pharmacol. Ther. 2023, 244, 108372. [Google Scholar] [CrossRef]
- FANG, Z.Q.; RUAN, B.; LIU, J.J.; et al. Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through endothelial nitric oxide synthase[J]. Hepatology 2022, 76(3), 742–758. [Google Scholar] [CrossRef]
- GREUTER, T.; YAQOOB, U.; GAN, C.; et al. Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo[J]. J. Hepatol. 2022, 77(3), 723–734. [Google Scholar] [CrossRef] [PubMed]
- ZHANG, L.F.; WANG, X.H.; ZHANG, C.L.; et al. Sequential Nano-Penetrators of Capillarized Liver sinusoids and Extracellular Matrix barriers for Liver Fibrosis Therapy[J]. ACS Nano 2022, 16(9), 14029–14042. [Google Scholar] [CrossRef] [PubMed]
- KOTSILITI, E. NAFLD prevalence in older patients with T2DM[J]. Nat. Rev. Gastroenterol. Hepatol. 2023, 20, 65. [Google Scholar] [CrossRef] [PubMed]
- GREENHILL, C. Hepatic T helper 17 cells implicated in NAFLD[J]. Nat. Rev. Endocrinol. 2021, 17, 449. [Google Scholar] [CrossRef]
- ISFAHANI, M.M.; SEPANLOU, S.G.; JOUKAR, F.; et al. Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study[J]. Sci. Rep. 2026, 16, 742. [Google Scholar] [CrossRef]
- HUANG, X.; LIU, X.; LI, X.; et al. Cullin-associated and neddylation-dissociated protein 1 (CAND1) alleviates NAFLD by reducing ubiquitinated degradation of ACAA2[J]. Nat. Commun. 2023, 14, 4620. [Google Scholar] [CrossRef]
- JIAO, Q.; REN, Y.; TENG, X.; et al. Positive feedback between histone H4K16 lactylation and glycolysis promotes MAFLD progression[J]. Hepatol. Int. 2025. [Google Scholar] [CrossRef]
- HAYAKAWA, S.; TAMURA, A.; NIKIFOROV, N.; et al. Activated cholesterol metabolism is integral for innate macrophage responses by amplifying Myd88 signaling[J]. JCI Insight 2022, 7(22), e138539. [Google Scholar] [CrossRef]
- RODRIGUEZ-ORTIGOSA, C.M.; CELAY, J.; OLIVAS, I.; et al. A GAPDH-mediated trans-nitrosylation pathway is required for feedback inhibition of bile salt synthesis in rat liver[J]. Gastroenterology 2014, 147(5), 1084–1093. [Google Scholar] [CrossRef]
- LI, Z.; KABIR, I.; JIANG, H.; et al. Liver serine palmitoyltransferase activity deficiency in early life impairs adherens junctions and promotes tumorigenesis[J]. Hepatology 2016, 64(6), 2089–2102. [Google Scholar] [CrossRef]
- WANG, Y.; NAKAJIMA, T.; GONZALEZ, F.J.; et al. PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice[J]. Int. J. Mol. Sci. 2020, 21(6), 2061. [Google Scholar] [CrossRef]
- CLEMENS, M.M.; KENNON-MCGILL, S.; VAZQUEZ, J.H.; et al. Exogenous phosphatidic acid reduces acetaminophen-induced liver injury in mice by activating hepatic interleukin-6 signaling through inter-organ crosstalk[J]. Acta Pharm. Sin. B 2021, 11(12), 3836–3846. [Google Scholar] [CrossRef] [PubMed]
- MASUBUCHI, Y.; BOURDI, M.; REILLY, T.P.; et al. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease[J]. Biochem Biophys. Res. Commun. 2003, 304(1), 207–212. [Google Scholar] [CrossRef] [PubMed]
- DEVARBHAVI, H.; ASRANI, S.K.; ARAB, J.P.; et al. Global burden of liver disease: 2023 update[J]. J. Hepatol. 2023, 79(2), 516–537. [Google Scholar] [CrossRef] [PubMed]
- HAN, Y.; LING, Q.; WU, L.; et al. Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization[J]. Gut Microbes 2023, 15(1), 2221485. [Google Scholar] [CrossRef]
- ETIENNE-MESMIN, L.; VIJAY-KUMAR, M.; GEWIRTZ, A.T.; et al. Hepatocyte Toll-Like Receptor 5 Promotes Bacterial Clearance and Protects Mice Against High-Fat Diet-Induced Liver Disease[J]. Cell. Mol. Gastroenterol. Hepatol. 2016, 2(5), 584–604. [Google Scholar] [CrossRef]
- YONG, Q.; HUANG, C.; CHEN, B.; et al. Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways[J]. Biomed. Pharmacother. Biomed. Pharmacother. 2024, 177, 116952. [Google Scholar] [CrossRef]
- HANDA, P.; VEMULAKONDA, A.; KOWDLEY, K.V.; et al. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?[J]. World J. Gastroenterol. 2016, 22(31), 6965–6971. [Google Scholar] [CrossRef]
- HU, R.; ZHAO, J.; CHENG, Y.; et al. Exogenous mitochondrial pretreatment enhances the therapeutic effect of UC-MSCs on NAFLD in type 2 diabetic mice by mediating mitochondrial transfer[J]. Stem Cells Int. 2025, 2025, 4639115. [Google Scholar] [CrossRef] [PubMed]
- HAN, J.J.; LI, J.; HUANG, D.H. Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying Circ-Tulp4 Attenuate Diabetes Mellitus with Nonalcoholic Fatty Liver Disease by Inhibiting Cell Pyroptosis through the HNRNPC/ABHD6 Axis[J]. Tissue Eng. Regen. Med. 2025, 22(1), 23–41. [Google Scholar] [CrossRef] [PubMed]
- XIAO, K.; LIU, C.; WANG, H.; et al. Umbilical cord mesenchymal stem cells overexpressing CXCR7 facilitate treatment of ARDS-associated pulmonary fibrosis via inhibition of Notch/Jag1 mediated by the Wnt/β-catenin pathway[J]. Biomed. Pharmacother. Biomed. Pharmacother. 2023, 165, 115124. [Google Scholar] [CrossRef]
- FENG, X.; LIU, J.; XU, Y.; et al. Molecular mechanism underlying the difference in proliferation between placenta-derived and umbilical cord-derived mesenchymal stem cells[J]. J. Cell. Physiol. 2020, 235(10), 6779–6793. [Google Scholar] [CrossRef] [PubMed]
- ZHANG, H.; LIU, P.; DENG, Y.; et al. Human umbilical cord-derived mesenchymal stem cells ameliorate non-alcoholic fatty liver disease via activating TFEB-mediated autophagy in male mice[J]. Stem Cell. Res. Ther. 2025, 17(1), 34. [Google Scholar] [CrossRef]
- TZOUANAS, C.N.; SHAY, J.E.S.; SHERMAN, M.S.; et al. Hepatic adaptation to chronic metabolic stress primes tumorigenesis[J]. Cell 2026, 189(2), 435–460.e28. [Google Scholar] [CrossRef]
- SUGIMOTO, A.; SAITO, Y.; WANG, G.; et al. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3[J]. Nature 2025, 640(8059), 752–761. [Google Scholar] [CrossRef]
- KIM, D.H.; KIM, M.K.; KIM, D.; et al. Liver cancer chronically exposed to palmitate acquires ferroptosis resistance via the downregulation of glutamine-driven hepcidin expression[J]. Metabolism 2026, 176, 156469. [Google Scholar] [CrossRef] [PubMed]
- LOU, G.; YANG, Y.; LIU, F.; et al. MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis[J]. J. Cell. Mol. Med. 2017, 21(11), 2963–2973. [Google Scholar] [CrossRef]
- SONG, X.J.; ZHANG, L.; LI, Q.; et al. hUC-MSC derived exosomal miR-124 promotes rat liver regeneration after partial hepatectomy via downregulating Foxg1[J]. Life Sci. 2021, 265, 118821. [Google Scholar] [CrossRef]
- SUN, Y.; ZHANG, C.; MA, Q.; et al. MiR-34a-HK1 signal axis retards bone marrow mesenchymal stem cell senescence via ameliorating glycolytic metabolism[J]. Stem Cell. Res. Ther. 2024, 15(1), 238. [Google Scholar] [CrossRef]
- YAN, X.; ZHANG, D.; WU, W.; et al. Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a[J]. Cancer Res. 2017, 77(23), 6704–6716. [Google Scholar] [CrossRef]
- ZHOU, X.; CUI, L.; ZHOU, X.; et al. Induction of hepatocyte-like cells from human umbilical cord-derived mesenchymal stem cells by defined microRNAs[J]. J. Cell. Mol. Med. 2017, 21(5), 881–893. [Google Scholar] [CrossRef]
- CHENG, F.; YANG, F.; WANG, Y.; et al. Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway[J]. J. Nanobiotechnology 2023, 21(1), 195. [Google Scholar] [CrossRef] [PubMed]
- HE, L.; WANG, X.; KANG, N.; et al. MiR-375 inhibits the hepatocyte growth factor-elicited migration of mesenchymal stem cells by downregulating Akt signaling[J]. Cell. Tissue Res. 2018, 372(1), 99–114. [Google Scholar] [CrossRef]
- ZHU, Y.; ZHANG, X.; YANG, K.; et al. Macrophage-derived apoptotic vesicles regulate fate commitment of mesenchymal stem cells via miR155[J]. Stem Cell. Res. Ther. 2022, 13(1), 323. [Google Scholar] [CrossRef] [PubMed]
- XIAO, X.; XU, M.; YU, H.; et al. Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src[J]. Signal Transduct. Target Ther. 2021, 6(1), 354. [Google Scholar] [CrossRef] [PubMed]
- WEISKIRCHEN, R.; TACKE, F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology[J]. Hepatobiliary Surg. Nutr. 2014, 3(6), 344–363. [Google Scholar] [PubMed]
- TZOUANAS, C.N.; SHAY, J.E.S.; SHERMAN, M.S.; et al. Hepatic adaptation to chronic metabolic stress primes tumorigenesis[J]. Cell 2026, 189(2), 435–460.e28. [Google Scholar] [CrossRef]
- FILLIOL, A.; SAITO, Y.; NAIR, A.; et al. Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis[J]. Nature 2022, 610(7931), 356–365. [Google Scholar] [CrossRef]
- ZHANG, D.; ABULITIPU, A.; PANG, P.; et al. ECM1 protects against liver steatosis through PCBP1-mediated iron homeostasis[J]. Hepatology 2026, 83(3), 603–622. [Google Scholar] [CrossRef]
- TZOUANAS, C.N.; SHAY, J.E.S.; SHERMAN, M.S.; et al. Hepatic adaptation to chronic metabolic stress primes tumorigenesis[J]. Cell 2026, 189(2), 435–460.e28. [Google Scholar] [CrossRef]
- XI, Y.; ZENG, W.; LUO, J.; et al. RYK is a GPNMB receptor that drives MASH[J]. Nature 2026. [Google Scholar] [CrossRef]
- WU, L.; WANG, J.; WANG, Y.; et al. CLCC1 governs ER bilayer equilibration to maintain lipid homeostasis[J]. Nature 2026, 88. [Google Scholar] [CrossRef] [PubMed]


Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).